2 research outputs found
Π Π΄Π²ΡΡ ΡΠΏΠΎΡΠΎΠ±Π°Ρ Π°Π½Π°Π»ΠΈΠ·Π° Π½Π°ΠΏΡΡΠΆΠ΅Π½Π½ΠΎΠ³ΠΎ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ Π²ΡΠ°ΡΠ°ΡΡΠ΅Π³ΠΎΡΡ Π΄ΠΈΡΠΊΠ° Ρ ΡΠ°Π·ΡΠ΅Π·Π°ΠΌΠΈ
Π Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΠ΅ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π·Π°Π΄Π°ΡΠΈ ΠΎ Π½Π°ΠΏΡΡΠΆΠ΅Π½ΠΈΡΡ
Π²ΠΎ Π²ΡΠ°ΡΠ°ΡΡΠ΅ΠΌΡΡ Π΄ΠΈΡΠΊΠ΅ Ρ ΡΠ°Π·ΡΠ΅Π·Π°ΠΌΠΈ Π΄Π²ΡΠΌΡ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ ΡΠΏΠΎΡΠΎΠ±Π°ΠΌΠΈ: Π΄Π»Ρ ΠΊΡΡΠ³ΠΎΠ²ΠΎΠ³ΠΎ Π΄ΠΈΡΠΊΠ° Ρ ΡΠ°Π·ΡΠ΅Π·Π°ΠΌΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΡ ΡΠ΅ΡΠ΅Π½ΠΈΠΉ ΠΏΠΎΡΡΠΎΠ΅Π½Ρ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΡΠΈΠ½Π°; Π΄Π»Ρ Π΄ΠΈΡΠΊΠ° Π±ΠΎΠ»Π΅Π΅ ΡΠ»ΠΎΠΆΠ½ΠΎΠΉ ΠΊΠΎΠ½ΡΠΈΠ³ΡΡΠ°ΡΠΈΠΈ - ΠΊΡΠ°Π΅Π²ΡΠ΅ ΡΡΠ»ΠΎΠ²ΠΈΡ Π½Π° Π²Π½Π΅ΡΠ½Π΅ΠΌ ΠΊΠΎΠ½ΡΡΡΠ΅ ΡΠ²ΠΎΠ΄ΡΡΡΡ ΠΊ ΠΈΠ½ΡΠ΅Π³ΡΠ°Π»ΡΠ½ΠΎΠΌΡ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ. ΠΡΠΌΠ΅ΡΠ°Π΅ΡΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΈΠ½ΡΠ΅Π³ΡΠ°Π»ΡΠ½ΡΡ
ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΉ.
ΠΡΠΈ ΡΠΈΡΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠ°, ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠΉΡΠ΅ ΡΡΡΠ»ΠΊΡ http://essuir.sumdu.edu.ua/handle/123456789/2971
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
BACKGROUND
Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent
ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data
are needed to determine its effects on ischemic events.
METHODS
We performed a multicenter, randomized, double-blind, placebo-controlled trial involving
patients with established cardiovascular disease or with diabetes and other risk factors, who
had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg
per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of
41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned
to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary
end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal
stroke, coronary revascularization, or unstable angina. The key secondary end point was a
composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
RESULTS
A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular
events) and were followed for a median of 4.9 years. A primary end-point event occurred in
17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients
in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001);
the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio,
0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed
according to a prespecified hierarchical schema, were significantly lower in the icosapent
ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs.
5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in
the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation
or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients
in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06).
CONCLUSIONS
Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded
by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361